Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure

Developmental Medicine and Child Neurology

Volumn 52, Issue 1, 2010, Pages 60-65

  Vuillerot, Carole ^a,b   Girardot, Françoise ^a,b   Payan, Christine ^c   Fermanian, Jacques ^d   Iwaz, Jean ^a,e,f,g   De lattre, Capucine ^a,b   Berard, Carole ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ DE LYON   (France)

^f UNIVERSITÉ LYON 1   (France)

^g LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MOTOR PERFORMANCE; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PHYSIOTHERAPY; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; STANDING; TREATMENT OUTCOME;

EID: 73249127551     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2009.03316.x     Document Type: Article

References (14)

1. Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord 1991, 1:19-29.
2. Sussman M. Duchenne muscular dystrophy. J Am Acad Orthop Surg 2002, 10:138-51.
3. Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. Dev Med Child Neurol 2006, 48:540-44.
4. Bérard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005, 15:463-70.
5. Bérard C, Payan C, Fermanian J, Girardot F. The Motor Function Measure, a tool of clinical evaluation for neuromuscular diseases. Validation study. Rev Neurol (Paris) 2006, 162:485-93. In French)
6. Motor Function Measure: User's Manual 2006, Evry, France, Association Française contre les Myopathies
7. Liang M, Fossel A, Larson M. Comparison of five health-status instruments for orthopaedic evaluation. Med Care 1990, 28:632-42.
8. Bjorgvinsson T, Kerr P. Use of a common language effect size statistic. Am J Psychiatry 1995, 152:151.
9. Allsop KG, Ziter FA. Loss of strength and functional decline in Duchenne's dystrophy. Arch Neurol 1981, 38:406-11.
10. Legrand-Persoz M, Persoz B, Boulvert E, Gros P, Dardel JP, Arhan P. Surveillance de l'évolution musculaire respiratoire dans la myopathie de Duchenne de Boulogne àévolution rapide: application au contrôle thérapeutique. Ann Med Phys 1979, 23:1-14.
11. Vignos PJ, Spencer GE, Archibald KC. Management of progressive muscular dystrophy of childhood. J Am Med Assoc 1963, 184:89-96.
12. Brooke MH, Fenichel GM, Griggs RC. Clinical investigation in Duchenne dystrophy: 2. Determination of the 'power' of therapeutic trials based on the natural history. Muscle Nerve 1983, 6:91-103.
13. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantification of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve 1982, 5:291-301.
14. Steffensen BF, Lyager S, Werge B, Rahbek J, Mattsson E. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy and spinal muscular atrophy. A longitudinal study. Dev Med Child Neurol 2002, 44:623-32.